Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 22, 2017 (10 years ago)

Ventolin HFA (Albuterol Sulfate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective Delivery System: Elevated number of units with out of specification results for leak rate.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Net Wt. 18 g inhalers, Rx only, GlaxoSmithKline, Research Triangle Park, NC 22709, NDC 0173-0682-20.

Affected NDC 0173-0682-20

Compare with the code on your package — it is the most precise check available.

Drug: Albuterol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ventolin Hfa
albuterol sulfate
NDC 00173-0682
90 ug/1 Aerosol, Metered
Respiratory (inhalation)
GlaxoSmithKline LLC Rx
Recalling firm
GlaxoSmithKline, LLC
NDC code
0173-0682-20
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0626-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Albuterol recalls

See all
Class III · Low risk

Albuterol Sulfate

Failed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.

Ongoing Stability / shelf life Cipla USA, Inc. NDC 69097-142-60 D-0593-2025
Class I · High risk

Albuterol Sulfate Inhalation Aerosol

Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

Terminated Packaging defect Cipla USA, Inc. NDC 69097-142-60 D-0938-2023

Other recalls by GlaxoSmithKline, LLC

All 2017 recalls
Class III · Low risk

Tivicay PD

Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.

Terminated Labeling / mix-up GlaxoSmithKline LLC NDC 49702-255-37 D-0544-2024
Class III · Low risk

Anoro Ellipta

Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification

Terminated Failed specification GlaxoSmithKline LLC NDC 0173-0869-10 D-0160-2024
Class III · Low risk

Tivicay (dolutegravir)

Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

Terminated Labeling / mix-up GlaxoSmithKline LLC NDC 49702-228-13 D-0896-2022
Class II · Moderate risk

Ventolin HFA

Defective Delivery System: Elevated number of units with out of specification results for leak rate

Ongoing Packaging defect GlaxoSmithKline, LLC NDC 0173-0682-20 D-0793-2017